Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
Bradley J. Monk(HonorHealth), Takafumi Toita(Okinawa Prefectural Chubu Hospital), Xiaohua Wu(Fudan University Shanghai Cancer Center), Juan Carlos Vázquez Limón(Hospital Civil de Guadalajara), R. Tarnawski(The Maria Sklodowska-Curie National Research Institute of Oncology), Masaki Mandai(Kyoto University), Ronnie Shapira‐Frommer(Sheba Medical Center), Umesh Mahantshetty(Tata Memorial Hospital), Maria Del Pilar Estevez-Diz(Universidade de São Paulo), Qi Zhou(Chongqing Cancer Hospital), Sewanti Limaye(Sir H.N. Reliance Foundation Hospital and Research Centre), Francisco Javier Ramírez Godinez(Hospital Civil de Guadalajara), Christina Oppermann Kussler(Hospital Mãe de Deus), Szilvia Varga(National Institute of Oncology), Natalia Valdiviezo(Instituto Nacional de Enfermedades Neoplásicas), Daisuke Aoki(Keio University), Manuel Leiva(Universidad Ricardo Palma), Jung‐Yun Lee(Yonsei University), Raymond Sulay(Perpetual Succour Hospital), Yulia Kreynina(Ministry of Health of the Russian Federation), Wen‐Fang Cheng(National Taiwan University), Felipe Rey, Yi Rong(Mayo Clinic Hospital), Guihao Ke(Fudan University Shanghai Cancer Center), Sophie Wildsmith(AstraZeneca (United Kingdom)), Andrew R. Lloyd(AstraZeneca (United Kingdom)), Hannah Dry(AstraZeneca (United States)), Ana T. Nunes(AstraZeneca (United States)), Jyoti Mayadev(University of California San Diego Medical Center)
Cited by 199
Abstract
Related Papers
No related papers found
Powered by citation graph analysis